Dare Bioscience Inc Stock Price, News & Analysis

Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will participate in a live panel discussion titled The Evolution of Birth Control on February 23, 2021, at 12:30 p.m. EST during the Women’s Health Innovation Series: Contraception Innovation Summit. The discussion will explore innovation challenges in birth control. Ms. Johnson will highlight Daré's commitment to women's health and the development of three innovative contraceptive candidates: Ovaprene®, DARE-LARC1, and ORB formulations. This virtual summit aims to enhance women's contraceptive experiences, featuring stakeholders from various sectors.

Daré Bioscience, a leader in women’s health, announced that CEO Sabrina Martucci Johnson will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will cover innovative developments in women's health, including Daré's unique product portfolio.

Following the event, a recording will be available on Daré's investor relations website until March 4, 2021. The company focuses on developing differentiated therapies in contraception, vaginal health, sexual health, and fertility.

Daré Bioscience, a leader in women’s health innovation, announced that its CEO, Sabrina Martucci Johnson, will join a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference from January 11-14, 2021. The chat will be available on-demand starting January 11, 2021, at 6:00 AM ET on the company's website and will remain accessible until January 25, 2021. Daré focuses on advancing innovative therapies for women's health, offering products like Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1.

Daré Bioscience has announced that its investigational treatment, DARE-BV1, has successfully met its primary and secondary endpoints in a Phase 3 trial for bacterial vaginosis, achieving significant clinical cure rates over placebo. The study involved 307 women, demonstrating a 70.2% cure rate at 21-30 days. The treatment has received Fast Track and QIDP designations from the FDA, with a New Drug Application (NDA) submission planned for the first half of 2021. These results indicate a promising new front-line option for women suffering from bacterial vaginosis.

Daré Bioscience (NASDAQ: DARE) reported its third-quarter financial results for 2020, highlighting significant advances in its product pipeline amid a challenging environment. The company is on track to complete the DARE-BVFREE pivotal study for bacterial vaginosis and anticipates FDA submission in the first half of 2021 if results are favorable. Total expenses increased, with R&D costs rising to approximately $6.2 million due to ongoing projects like DARE-BV1 and Ovaprene. Cash and equivalents stand at $5.4 million, with recent capital raised of about $4.5 million post-quarter.

Daré Bioscience (NASDAQ: DARE) will host a conference call on November 12, 2020, at 4:30 p.m. ET to discuss its financial results for Q3 2020. The event will provide insights into the company's portfolio focused on women's health, including innovative products like Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. Investors can join via phone or webcast, with a replay available until November 19, 2020. The company's mission is to enhance treatment options in areas including contraception and male sexual health.

Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will present at the 2020 BIO Investor Forum, held digitally from October 13-15, 2020. Registered attendees can access the presentation on demand during the event. Following the forum, a recording will be available in the Investor Relations section of the company's website until October 29, 2020. Daré is focused on innovative women's health products, including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1, enhancing treatment options across various areas including contraception and sexual health.

Daré Bioscience (NASDAQ: DARE) announced the receipt of approximately $0.9 million in funding from the Bill & Melinda Gates Foundation, completing a total of $19.5 million in grant support for its user-controlled long-acting reversible contraceptive (UC-LARC), DARE-LARC1. This funding will aid in advancing the preclinical development of DARE-LARC1, designed to deliver therapeutic doses without requiring medical procedures. The technology, developed by MIT researchers, aims to address the limitations of current LARCs, offering a more flexible contraceptive solution.

Daré Bioscience, focused on women’s health, announced CEO Sabrina Martucci Johnson's participation in two virtual conferences on September 14 and 15, 2020. She will join the Women’s Health Innovation Summit's expert panel for women-centric clinical research and a CEO leadership panel, with both discussions available on-demand. Additionally, Johnson will present a company update at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:00 PM EDT. Live webcasts and an archive will be accessible through the company's website.